News 
Market Data 
Discover
Replies to post #213558 on Biotech Values
Compelling open-label data: no febrile neutropenia (FN) in 51 patients,
>250 cycles chemo (historical FN rates ~ 30% with topotecan)
• In this ongoing study, the combination of trilaciclib with topotecan is well tolerated, without any episodes of febrile
neutropenia or treatment-related SAEs
• The most common adverse events were hematologic toxicities attributed to chemotherapy; in the setting of frequent
hematologic monitoring, Grade 3/4 events recovered quickly, were associated with fewer topotecan dose
delays/reductions and less growth factor usage and transfusions than those reported in the literature
• A pharmacologic drug-drug interaction resulting in reduced topotecan clearance and consequent increase in
topotecan exposure was identified; however, exposures at a topotecan dose of 0.75 mg/m2 with trilaciclib were
comparable to those reported in the literature for 1.5 mg/m2 topotecan alone
• Early anti-tumor results (ORR and CBR) are encouraging
• This novel approach, allowing the administration of chemotherapy with preservation of HSC and immune system
function, could potentially improve treatment outcomes for patients with CDK4/6-independent tumors
GTHX:
Been watching it for a while. Looked into it a while ago and decided I wasn't too impressed. But now we see what that opinion is worth!
On a fundamental basis, I'm really not sure why it's ramping up. The data aren't all that clear for its lead product.
06/18/19 12:06 PM
09/30/19 4:35 PM
02/13/23 9:10 AM
